Results 171 to 180 of about 1,327 (186)

Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review

Annals of Pharmacotherapy, 2021
Alicia Potter DeFalco
exaly  

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Headache, 2020
Richard B Lipton
exaly  

Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System

Expert Opinion on Drug Safety, 2023
Vera Battini, Carla Carnovale, Maurizio Sessa   +2 more
exaly  

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)

Advances in Therapy, 2022
Lauren Powell, Richard B Lipton, Evan Popoff   +2 more
exaly  

Rimegepant bei Migräne effektiver als Placebo

Neurologie up2date, 2020
openaire   +1 more source

Rimegepant (Nurtec ODT)for Acute Treatment of Migraine

JAMA, 2020
openaire   +2 more sources

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Lancet, The, 2019
Peter Goadsby, Richard B Lipton
exaly  

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

Lancet Neurology, The, 2023
exaly  

Rimegepant (Nurtec ODT) for acute treatment of migraine.

The Medical letter on drugs and therapeutics, 2020
openaire   +1 more source

Rimegepant (Migräneprophylaxe); Nutzenbewertung gemäß § 35a SGB V

openaire   +1 more source